Thursday, June 30, 2016

11.15 - 12.00FID Board MeetingKursraum 4, U1
12.30 - 13.30Lunch symposium (Sponsored by Boehringer Ingelheim)
Beyond glucose: From surrogate markers to endpoints - the impact of outcome studies in the treatment of T2D
Chair: P. Diem, Bern
Auditorium Rossi
H. Drexel, Feldkirch
Reduction of mortality in high risk patients with Empagliflozin - implications for treatment decisions in T2D
A. Zanchi, Lausanne
Influence of kidney function on treatment choices in T2D - a Swiss example
13.45 - 14.10Welcome address
R. Lehmann, Zurich; P. Diem, Bern
Auditorium Rossi
14.10 - 15.30Opening session
Chair: P. Diem, Bern; R. Lehmann, Zürich
Auditorium Rossi
14.10 - 14.50P. Scherer, Dallas
The role of the adipose tissue in diabetes and obesity
14.50 - 15.30H. Steinke, Bern
Johann Conrad Brunner and his studies on pancreatectomy
15.30 - 16.00Coffee breakKursraum 1, Foyer
16.00 - 17.40Session 1: Update on novel treatment options in diabetes and metabolism
Chair: E. Christ, Bern; W. Waldhäusl, Vienna
Auditorium Rossi
16.00 - 16.25R. Weitgasser, Salzburg
New insulins
16.25 - 16.50M. Nauck, Bochum
16.50 - 17.15C. Ebenbichler, Innsbruck
New treatment options for hypercholesterolemia
17.15 - 17.40N.C. Schloot, Düsseldorf
Diabetes disease classification: relevance to pathophysiology and treatment
17.40 - 18.00Coffee breakKursraum 1, Foyer
18.00 - 19.00Satellite symposium (Sponsored by Novo-Nordisk)
Beyond glucose lowering: GLP-1 effects on body weight and cardiovascular system
Chair: M. Donath, Basel
Auditorium Rossi
J.J. Holst, Kopenhagen and S. Bilz, St. Gallen
19.30Welcome receptionInselspital, main building, top floor